Welcome to our dedicated page for NEUROCRINE BIOSCIENCES SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences Chief Commercial Officer filed an amended Form 4 to correct a previously misreported stock option exercise. On November 28, 2025, the insider exercised 12,830 incentive stock options, rather than the 5,970 options originally reported. The options had an exercise price of $35.99 per share and converted into an equal number of common shares. The filing also updates the insider’s reported beneficial ownership of Neurocrine Biosciences common stock and notes that this total includes 204 shares acquired through the company’s 2018 Employee Stock Purchase Plan. The incentive stock option was granted on February 5, 2016, vested in 48 equal monthly installments beginning March 5, 2016, and was scheduled to expire on February 5, 2026.
A holder of NBIX common stock has filed a notice of proposed sale under Rule 144, covering 36,400 common shares with an aggregate market value of $4,853,940. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 01/16/2026. Common shares outstanding were 99,705,698 as of this notice.
The 36,400 shares were acquired on 01/16/2026 by exercising stock options granted by the issuer and paid for in cash. In the past three months, the seller listed as Kyle Gano previously sold 300 common shares on 11/04/2025 for gross proceeds of $42,591. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s operations.
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 3,349 shares of common stock on January 8, 2026. The options had an exercise price of $35.99 per share and were originally granted on February 5, 2016, vesting monthly over four years and scheduled to expire on February 5, 2026.
Following the option exercise, Lippoldt directly held 46,754 shares of Neurocrine Biosciences common stock, and the reported incentive stock option position was reduced to zero.
A director of Neurocrine Biosciences, Inc. reported stock transactions in mid-December 2025. On December 15, 2025, the director exercised 8,276 stock options at $92.35 per share and 1,724 options at $84.95 per share, converting them into common stock. That same day, the director sold 5,000 shares of common stock at a weighted average price of $152.2287 per share, followed by an additional sale of 1,190 shares on December 16, 2025 at a weighted average price of $155.0911 per share. After these trades, the director beneficially owned 6,239 shares of Neurocrine common stock. The filing notes that the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, and that company policy restricts changes to such plans after adoption.
Neurocrine Biosciences reports that Chief Scientific Officer Jude Onyia settled restricted stock units on November 29, 2025, receiving 4,426 shares of common stock. To satisfy tax obligations, 2,248 shares were withheld at $152.16 per share, and no shares were sold. Following these transactions, Onyia directly holds 15,881 common shares.
Neurocrine Biosciences (NBIX) reported an insider equity transaction by a director. On 11/25/2025, the reporting person exercised a non-qualified stock option for 15,000 shares of common stock at an exercise price of $47.89 per share and acquired those shares.
On the same date, the director disposed of 15,000 shares of common stock in an open-market sale coded "S," at a weighted average price of $143.3675 per share, executed under a Rule 10b5-1 trading plan adopted on August 26, 2025. After these transactions, the reporting person directly beneficially owned 7,068 shares of Neurocrine common stock.
Neurocrine Biosciences, Inc. (NBIX) reported an update to its senior leadership arrangements. Former Chief Medical Officer Eiry W. Roberts, M.D., who transitioned to the role of Strategic Advisor effective June 2, 2025, will continue in that advisory role for an additional 12 months. On November 21, 2025, the company and Dr. Roberts entered into an amendment to her amended and restated employment agreement to extend her employment term through December 31, 2026.
The amendment is filed as an exhibit to this report, reflecting the company’s decision to retain Dr. Roberts’ expertise in a strategic advisory capacity following the appointment of Sanjay Keswani, M.D. as Chief Medical Officer.
Neurocrine Biosciences (NBIX) reported an insider transaction. On 11/05/2025, a director exercised 18,000 non-qualified stock options at an exercise price of $47.89 per share and sold 18,000 common shares at a weighted average price of $151.8161. The sale was executed under a Rule 10b5-1 trading plan adopted on August 6, 2025.
Following these transactions, the reporting person beneficially owned 40,360 shares, held by the Rastetter Family Trust. The option was granted on May 20, 2016 and was due to expire on May 20, 2026.
Neurocrine Biosciences (NBIX) CEO and director reported Form 4 activity. On 11/01/2025, 613 shares of common stock were acquired at $0 upon RSU vesting.
On 11/04/2025, 300 shares were sold at $141.97. The filing states these mandatory sales were made to cover withholding taxes and are intended to meet Rule 10b5-1(c). After these transactions, directly held shares were 140,407, and derivative holdings (RSUs) were 1,842. Beneficial ownership includes 200 shares purchased on 02/28/2025 under the company’s ESPP.
Neurocrine Biosciences reported strong Q3 2025 results, with total revenues of $794.9 million, up from $622.1 million a year ago. Growth was driven by INGREZZA net product sales of $686.6 million and the U.S. launch of CRENESSITY contributing $98.1 million. Operating income was $239.0 million and net income reached $209.5 million, translating to diluted EPS of $2.04 versus $1.24 last year.
The company continued to invest for growth: research and development expense rose to $250.0 million and selling, general, and administrative expense to $291.6 million. Year to date, cash flows from operating activities were $394.3 million. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $2,113.3 million, with working capital of $1,520.4 million. Neurocrine repurchased 1.8 million shares for $227.2 million during the first nine months of 2025 under its $500 million authorization and completed a $300 million accelerated repurchase begun in 2024. Shares outstanding were 99,705,698 as of October 21, 2025.